SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $78.2 million in its third quarter.
The South San Francisco, California-based company said it had a loss of 57 cents per share.
The results fell short of Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 56 cents per share.
The immuno-oncology company posted revenue of $49,000 in the period.
Allogene Therapeutics shares have fallen 23% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.43, a fall of 37% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News